Results 1 to 10 of about 175,605 (302)

Safety and efficacy of a feed additive consisting of riboflavin 80% (vitamin B₂) produced with <i>Saccharomyces cerevisiae</i>ATCC SD-8628 for all animal species (Amyris Inc). [PDF]

EFSA J
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Villa RE, Azimonti G, Bonos E, Christensen H, Durjava M, Dusemund B, Gehring R, Glandorf B, Kouba M, López-Alonso M, Marcon F, Martelli G, Nebbia C, Pechová A, Prieto-Maradona M, Theodoridou K, Yurkov A, Mayo B, Brozzi R, Galobart J, Pettenati E, Vettori MV, Pizzo F.   +23 more
europepmc   +1 more source

Neurochemical Endpoints to Inform Early‐Stage Trials of Spinocerebellar Ataxia 2 and 3 in a Multisite Setting

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neurochemical levels measured by brain MR spectroscopy (MRS) have been proposed as endpoints for clinical trials in early‐stage spinocerebellar ataxia (SCA) trials. We tested their trial‐readiness by quantifying neurochemicals in three affected brain regions in early‐stage cohorts of SCA2 and SCA3, examining their reproducibility in ...
James M. Joers, Yaqiao Wei, Dinesh K. Deelchand, Adam Berrington, Young Woo Park, Guita Banan, Michal Povazan, Jens T. Rosenberg, André J. W. van der Kouwe, Tetsuo Ashizawa, Khalaf O. Bushara, Chiadi U. Onyike, Sub H. Subramony, Jeremy D. Schmahmann, Brian J. Soher, Peter B. Barker, Thomas H. Mareci, Eva‐Maria Ratai, Lynn E. Eberly, Gülin Öz   +19 more
wiley   +1 more source

Safety evaluation of an extension of use of the food enzyme subtilisin from the non-genetically modified <i>Bacillus licheniformis</i> strain NZYM-CX. [PDF]

EFSA J
EFSA Panel on Food Enzymes (FEZ), Zorn H, Barat Baviera JM, Bolognesi C, Catania F, Gadermaier G, Greiner R, Mayo B, Mortensen A, Roos YH, Solano MLM, Van Loveren H, Vernis L, Rosell AF, Cavanna D, Liu Y.   +15 more
europepmc   +1 more source

Cognitive and Neuroimaging Divergence Between Juvenile and Adult FUS Amyotrophic Lateral Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive motor neuron degeneration. Fused in sarcoma (FUS)‐associated juvenile ALS (jALS) represents a distinct and aggressive subgroup with rapid deterioration and poor prognosis.
Alexandra V. Jürs, Marcel Naumann, Annaliis Lehto, Hanna Schön, Jens Kurth, Johannes Prudlo, Andreas Hermann, Elisabeth Kasper   +7 more
wiley   +1 more source

Safety evaluation of an extension of use of the food enzyme subtilisin from the genetically modified <i>Bacillus licheniformis</i> strain NZYM-CB. [PDF]

EFSA J
EFSA Panel on Food Enzymes (FEZ), Zorn H, Barat Baviera JM, Bolognesi C, Catania F, Gadermaier G, Greiner R, Mayo B, Mortensen A, Roos YH, Solano MLM, Van Loveren H, Vernis L, Tokić V, Cavanna D, Liu Y.   +15 more
europepmc   +1 more source

The Multiple Sclerosis Severity Allele rs10191329A and Cognitive Function: A UK Biobank Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The genome‐wide association study of Multiple Sclerosis severity linked the genetic variant rs10191329A to long‐term disability and implicated brain resilience as a determinant of outcome. We hypothesised that rs10191329A might influence cognition in other neurological diseases and healthy controls.
Ioanna Zimianiti, Sheena Waters, Adil Harroud, Pernilla Stridh, Ruth Dobson, Benjamin M. Jacobs   +5 more
wiley   +1 more source

Efficacy of genetically modified Mycoplasma hyopneumoniae strains and their effect on local and cell-mediated immune responses in pigs. [PDF]

Vet Res
Beuckelaere L, Boyen F, Auray G, Haspeslagh M, De Coensel E, Trueeb BS, Meyer E, Haesebrouck F, De Spiegelaere W, Devriendt B, Summerfield A, Kuhnert P, Maes D.   +12 more
europepmc   +1 more source

Creation of Genetically Modified Animals

, 2016
Belen Pintado, Marian van Roon
openaire   +1 more source

Addressing Economic Insecurities Can Improve Patient‐Reported Outcomes in Lupus

Arthritis Care &Research, EarlyView.
Objective Economic insecurities, such as food, housing, transportation, and financial challenges, are modifiable risk factors and influence patient‐reported outcomes (PROs) in systemic lupus erythematosus (SLE). We examined the following: (1) associations between economic insecurities and PROs, and (2) the impact of screening and addressing economic ...
Jay Patel, Tripti Singh, Meredith Ingersoll, Shelby Gomez, Amanda Weber, Sarah E. Panzer, Sancia Ferguson, Christie M. Bartels, Shivani Garg   +8 more
wiley   +1 more source

Regulatory provisions for post-release monitoring of genetically modified organisms in Africa. [PDF]

Front Bioeng Biotechnol
Njagi J, Muriuki J, Mbugua P, Dass B, James S, Ogoyi D.   +5 more
europepmc   +1 more source